Prime Medicine (NYSE:PRME – Get Free Report) and Achilles Therapeutics (NASDAQ:ACHL – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, risk and dividends.
Institutional & Insider Ownership
70.4% of Prime Medicine shares are owned by institutional investors. Comparatively, 56.4% of Achilles Therapeutics shares are owned by institutional investors. 23.5% of Prime Medicine shares are owned by company insiders. Comparatively, 5.4% of Achilles Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Prime Medicine and Achilles Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Prime Medicine | $800,000.00 | 475.46 | -$198.13 million | ($2.05) | -1.41 |
| Achilles Therapeutics | N/A | N/A | -$69.67 million | ($1.65) | -0.84 |
Profitability
This table compares Prime Medicine and Achilles Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Prime Medicine | N/A | -107.87% | -74.97% |
| Achilles Therapeutics | N/A | -54.45% | -47.68% |
Risk & Volatility
Prime Medicine has a beta of 1.86, indicating that its stock price is 86% more volatile than the S&P 500. Comparatively, Achilles Therapeutics has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Prime Medicine and Achilles Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Prime Medicine | 0 | 0 | 9 | 1 | 3.10 |
| Achilles Therapeutics | 0 | 1 | 1 | 0 | 2.50 |
Prime Medicine presently has a consensus target price of $13.13, indicating a potential upside of 352.59%. Achilles Therapeutics has a consensus target price of $4.00, indicating a potential upside of 189.86%. Given Prime Medicine’s stronger consensus rating and higher possible upside, research analysts plainly believe Prime Medicine is more favorable than Achilles Therapeutics.
Summary
Prime Medicine beats Achilles Therapeutics on 8 of the 13 factors compared between the two stocks.
About Prime Medicine
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.
About Achilles Therapeutics
Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.
Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
